Warm Springs Advisors Inc. Makes New $652,000 Investment in Boston Scientific Co. (NYSE:BSX)

Warm Springs Advisors Inc. bought a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 7,296 shares of the medical equipment provider's stock, valued at approximately $652,000.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Parnassus Investments LLC raised its position in Boston Scientific by 0.7% during the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after purchasing an additional 97 shares during the last quarter. Baldwin Investment Management LLC increased its stake in shares of Boston Scientific by 1.2% in the fourth quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after buying an additional 102 shares during the period. Evergreen Capital Management LLC raised its position in shares of Boston Scientific by 1.7% during the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after acquiring an additional 106 shares during the last quarter. PDS Planning Inc lifted its stake in shares of Boston Scientific by 1.5% in the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after acquiring an additional 113 shares during the period. Finally, Adero Partners LLC increased its position in Boston Scientific by 3.3% during the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after purchasing an additional 120 shares during the period. Institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the topic of several recent analyst reports. BTIG Research restated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, April 23rd. Argus set a $130.00 price objective on shares of Boston Scientific in a research note on Tuesday, February 18th. Morgan Stanley increased their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Barclays lifted their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Wells Fargo & Company raised their target price on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Twenty-two research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and an average target price of $114.87.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.08 during trading on Thursday, reaching $104.59. 3,410,219 shares of the stock traded hands, compared to its average volume of 7,612,283. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock has a market capitalization of $154.74 billion, a P/E ratio of 83.67, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a 50-day moving average of $100.22 and a 200-day moving average of $97.66.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the firm earned $0.56 earnings per share. The company's revenue was up 20.9% compared to the same quarter last year. Analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the transaction, the executive vice president now owns 22,235 shares of the company's stock, valued at $2,269,304.10. The trade was a 43.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 191,155 shares of company stock valued at $19,556,047. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.